Clinically Relevant CHK1 Inhibitors Abrogate Wild-Type and Y537S Mutant ERα Expression and Proliferation in Luminal Primary and Metastatic Breast Cancer Cells

The authors evaluated if kinases could be new targets for the treatment of luminal primary and metastatic breast cancers.
[Journal of Experimental & Clinical Cancer Research]

Sorry, but the selected Zotpress account can't be found.

Full Article